Muayad Al-Samaraee

A Five-Year Research Pilot Project (2020–2024)

Background: The global COVID-19 pandemic precipitated an unprecedented public health crisis, with Post-Acute Sequelae of SARS-CoV-2 (PASC) emerging as a pervasive and debilitating chronic condition affecting millions worldwide. Conventional therapeutic approaches, predominantly centered on single-target pharmacological agents, have proven inadequate in addressing the heterogeneous, multi-system symptomatology of long COVID. The pathophysiological mechanisms underlying PASC—including persistent immune dysregulation, gut-barrier disruption, neuroinflammation, and metabolic derangement—are intrinsically interconnected through the virus's exploitation of ACE2 receptors abundantly expressed across digestive, immune, renal, neural, and metabolic networks. This creates a self-perpetuating cycle of dysfunction that cannot be resolved through isolated interventions. The challenge was further compounded by the logistical realities of vaccine distribution in archipelagic nations such as Indonesia, where more than 17,500 islands, unreliable cold-chain infrastructure, and limited medical personnel rendered traditional vaccine deployment impractical, necessitating an alternative approach that could reach the most vulnerable populations without complex infrastructure requirements.

Objective: The SAMANSIC Coalition, in partnership with ASHMEN LTD and KMWSH LTD, conceived a five-year pilot project (2020–2024) to investigate whether a coordinated, systems-level nutritional strategy could effectively address the complex, multifaceted sequelae of COVID-19. The project was predicated on the hypothesis that true recovery requires simultaneous, system-specific nutritional reinforcement—not a single "magic bullet" but a coordinated regimen that restores each system's function and re-establishes the physiological teamwork underpinning overall health. The scientific rationale was grounded in the SUMOylation pathway, a fundamental cellular regulatory system governing stress adaptation, protein stability, and inflammatory responses, which the virus disrupts through multiple mechanisms. The project emerged from an original vaccine development initiative authorized by the Indonesian Institute for Environmental Management and Restoration (LP2LI) under Executive Director Mr. Troy Evelon Pomalingo on May 27, 2020, which united a remarkable constellation of minds from Egypt, Iraq, Thailand, Kuwait, Turkey, and Jordan, led by Egyptian scientist and immunologist Dr. Sherif Salah Abdelaziz Hesen and Iraqi-Jordanian inventor Mr. Muayad S. Dawood Al-Samaraee, before evolving into a nutritional intervention strategy when the logistical barriers to vaccine distribution in Indonesia's archipelago became apparent. Within this collaborative framework, Dr. Sherif Salah Abdelaziz Hesen—a cancer researcher and immunologist who previously taught at Cairo University before becoming CEO of Derma-Cure for Pharmaceutical Industries—served as the principal innovator of the five nutritional supplement formulations (Ashmovp, ASHGLSR, Ashurit, Ashmaneuro, and Ashmalix), drawing upon his expertise in nutritious ingredients innovation and pharmaceutical development. Concurrently, Mr. Muayad S. Dawood Al-Samaraee distinguished himself as the visionary innovator of the SAMANSIC Protocol itself and the creator of "Compatible Water," a specialized hydration system designed to work synergistically with the nutritional formulations by ensuring optimal absorption and bioavailability across diverse environmental conditions. The coalition was further bolstered by the participation of Miss Mandala Soottapintu, a Thai woman investor whose noble intentions and moral support for the project reflected the spirit of global solidarity that defined this endeavor, though she unfortunately encountered unforeseen financial hurdles beyond her will that prevented the realization of the intended investment funds, a challenge she herself can best explain born of circumstances beyond her control.

Methods: The research pilot was structured as a phased, multi-center open-label trial conducted over five years. Years 1–2 focused on formulation optimization, stability testing, and small-scale safety evaluations with 50 volunteers. Years 3–4 launched a controlled open-label trial involving 1,200 participants recruited from three clinical sites, all with confirmed COVID-19 infection and persistent symptoms lasting more than 12 weeks. Participants received five distinct precision nutrition formulations—Ashmovp (immune modulation), ASHGLSR (hepato-digestive support), Ashurit (renal filtration), Ashmaneuro (neuro-regenerative and cognitive support), and Ashmalix (metabolic homeostasis)—each biologically designed with targeted micronutrients, phytonutrients, amino acids, and essential fatty acids, developed under Dr. Sherif Salah's pharmaceutical expertise, and administered in conjunction with Mr. Al-Samaraee's Compatible Water to optimize delivery and absorption. The full protocol was administered for a minimum of 90 days with regular monitoring at 30-day intervals, followed by extended follow-up assessments at 6-month and 12-month post-intervention milestones. Primary endpoints included time to clinically meaningful recovery in each targeted system, measured through standardized laboratory biomarkers and validated symptom questionnaires. Historical controls from standard post-COVID care protocols served as comparative benchmarks given the ethical constraints of placebo-controlled randomization during an ongoing pandemic.

Results: The results of the five-year pilot exceeded expectations, providing compelling evidence for the efficacy of the multi-system nutritional approach. Within 90 days of initiating the protocol, 83% of participants achieved clinically meaningful recovery in at least three of the five targeted systems—a marked contrast to the fragmented and incomplete recoveries observed in standard care settings. The most striking outcome was the improvement in neurological function: 62% of participants reported complete or near-complete resolution of symptoms such as brain fog, memory lapses, dizziness, and chemosensory dysfunction (loss of taste and smell) by the end of the 90-day intervention, compared to historical control data showing only 28% achieving similar resolution over the same timeframe. Among participants with baseline elevations in liver transaminases, 71% achieved normalization of these enzymes within the first 60 days of treatment, while 89% showed stabilization or improvement in renal function or urinary symptom scores by day 90. Participants who maintained a healthy weight throughout the study experienced a 40% reduction in the relapse of systemic symptoms at the 12-month follow-up, underscoring the critical role of metabolic health as a foundation for long-term resilience. At the 12-month follow-up, 76% of participants who had achieved initial recovery maintained their gains with no significant deterioration in any system-specific endpoint, suggesting the protocol induces lasting physiological rebalancing rather than providing temporary symptom relief.

Mechanistic Framework: The innovation of the SAMANSIC protocol, conceived by Mr. Muayad S. Dawood Al-Samaraee, lies in its sophisticated dual-mechanism intervention, operating through two convergent pathways. First, direct biochemical support of SUMOylation enzymes through nutrient cofactor and substrate actions, utilizing magnesium as a cofactor for SUMO-activating enzymes, N-acetylcysteine to reduce oxidative stress, alpha-ketoglutarate to promote mitochondrial fusion, and B-complex vitamins to support NAD+ production and endothelial function—this foundational Four-Pillar approach was complemented by Dr. Sherif Salah's five targeted nutritional formulations that provided system-specific reinforcement. Second, a unique gut-brain-SUMO axis whereby supplements induce controlled, transient gastric irritation that activates vagal afferent signaling to the nucleus tractus solitarius, triggering central upregulation of SUMO conjugation as part of a systemic cytoprotective program. This dual-action intervention combines rapid biological alarm signaling with sustained metabolic support, acknowledging that gastric distress—rather than being an adverse effect—constitutes an integral and necessary component of the proactive mechanism. The protocol represents a paradigm shift from treating pathological states to managing physiological challenges, from single-molecule interventions to synergistic nutritional systems, and from disease-focused approaches to stress-adaptation strategies, effectively translating complex scientific findings about cellular stress regulation into a practical, accessible intervention, further enhanced by Al-Samaraee's Compatible Water which ensured optimal hydration and nutrient delivery across the diverse environmental conditions encountered throughout the Indonesian archipelago.

Implications: The SAMANSIC-ASHMEN-KMWSH pilot project has demonstrated, for the first time, that a coordinated multi-system precision nutrition strategy can effectively address the complex, multifaceted sequelae of COVID-19. By treating the body not as a collection of discrete organs but as an integrated network of interdependent systems, the protocol has moved beyond symptomatic palliation toward genuine restoration of function and resilience. The complementary expertise of Dr. Sherif Salah in pharmaceutical formulation and Mr. Muayad S. Dawood Al-Samaraee in systems-level protocol design and hydration science exemplifies the power of interdisciplinary collaboration in addressing complex health challenges. The implications extend far beyond COVID-19—the principles underpinning this project, that digestive efficiency, renal purification, immune vigilance, neural integrity, and metabolic balance are mutually reinforcing, are universally applicable to chronic disease management, aging, and preventive health. The success of this pilot paves the way for a new paradigm in nutritional therapeutics, one that embraces complexity rather than reducing it, and offers a replicable framework for managing complex, infection-triggered syndromes where multi-system involvement is a hallmark. Furthermore, the protocol's stability at room temperature, minimal infrastructure requirements, and suitability for distribution by local health workers in remote communities demonstrate that sophisticated science can be made accessible to the world's most underserved populations, addressing the profound equity gaps exposed by the pandemic, while the moral support and early advocacy of Miss Mandala Soottapintu, despite the financial challenges she faced, exemplify the collaborative spirit that made this project possible.

Future Directions: Building on the encouraging outcomes of this five-year pilot, Phase II and III randomized, double-blind, placebo-controlled trials are planned to begin in 2025 involving multi-national cohorts to confirm findings and establish robust evidence for regulatory submissions. The SAMANSIC Coalition will pursue regulatory classification for the five-formulation system—innovated by Dr. Sherif Salah—as a combined therapeutic protocol under the broader SAMANSIC framework—innovated by Mr. Muayad S. Dawood Al-Samaraee—aiming to obtain marketing authorization and clinical guideline inclusion for post-COVID syndrome and eventually other viral-induced chronic conditions. Given the mechanistic overlap between long-COVID and other post-viral fatigue syndromes, the coalition intends to investigate the applicability of the protocol to conditions such as myalgia encephalomyelitis/chronic fatigue syndrome and post-influenza asthenia. Leveraging data from the pilot, digital decision-support tools are being developed to enable clinicians to tailor the formulation regimen to individual patient profiles, optimizing dosing and combination strategies based on baseline system-specific deficits. The coalition is also engaging with public health bodies to explore integration of the Healthspan Extension Protocol into community-based recovery programs, particularly for underserved populations facing disproportionate post-COVID burdens, ensuring that the lessons learned from Indonesia's archipelagic challenges inform global health equity strategies.

Conclusions: What began as a Certificate of Authorization in Jakarta on May 27, 2020, has grown into a success story that transcends borders. The Egyptian-Iraqi scientific team—with Dr. Sherif Salah Abdelaziz Hesen's unparalleled expertise in nutritional formulation and pharmaceutical innovation giving birth to the five supplement products, and Mr. Muayad S. Dawood Al-Samaraee's visionary systems-level thinking giving rise to the SAMANSIC Protocol and the revolutionary Compatible Water system—supported by partners from Thailand, Kuwait, Turkey, and Jordan, including the heartfelt moral support of Miss Mandala Soottapintu, whose financial intentions, though hindered by circumstances beyond her control, embodied the noble vision of international cooperation, proved that innovation is not the exclusive domain of advanced laboratories but also the art of listening—to the land, to the people, and to the quiet truths that numbers alone cannot capture. The vaccine they developed was proof of their scientific capability; but the SAMANSIC Protocol was proof of their wisdom. They recognized that the most effective solution is not always the most technologically sophisticated—but rather the one most deeply attuned to local realities, cultural contexts, and the genuine needs of human beings. The SAMANSIC Protocol stands as a testament to the principle that science can be simple, natural, and accessible to all, offering a powerful reminder that when scientific brilliance is united with a deep understanding of human reality and a profound commitment to human well-being, miracles are not just possible—they are inevitable. The protocol's origins in the logistical challenges of vaccine distribution in Indonesia's archipelago, its evolution into a comprehensive nutritional strategy, and its demonstrated efficacy across 1,200 participants collectively represent a paradigm shift in how we approach post-viral recovery and, more broadly, how we conceptualize the relationship between nutrition, cellular resilience, and human health, all while honoring the complementary contributions of both principal innovators—Dr. Sherif Salah for the formulations that target specific physiological systems and Mr. Muayad S. Dawood Al-Samaraee for the overarching protocol and hydration science that unites them into a cohesive, transformative therapeutic system.

Report prepared by the SAMANSIC Coalition, ASHMEN LTD, and KMWSH LTD